[LHN]
Subscribe
Open menu
MethodologySubmit a ClaimMedical Disclaimer

Does TB-500 speed injury recovery?

TB-500 is promoted online as a peptide that speeds soft-tissue recovery.

LHN branded editorial cover for claim check: Does TB-500 speed injury recovery?.

Simple answer

TB-500 injury-recovery claims are not supported by strong human clinical evidence. The claim often relies on extrapolation from thymosin beta-4 biology and should be treated as unproven. The safer reading is: do not treat social media or clinic marketing as proof, and do not use this page for medical decisions.

Bottom line at a glance

Bottom line:Not provenEvidence:Early theoryRisk:High riskStatus:Not approved
What does evidence mean?
The biology may make sense, but outcomes in people are not established.
Why risk matters
Do not use this page for dosing, sourcing or self-administration decisions.
Approval status
Do not read online claims as FDA approval.

Last checked: Jun 27, 2026

What people claim

The common claim is broader than the regulatory and human-evidence record.

What we know

  • Mechanistic interest does not establish consumer recovery benefit.
  • Human evidence for broad injury recovery is not strong enough for a positive verdict.
  • FDA compounding review language is use-specific and not the same as consumer approval.

What we do not know

  • It does not prove faster recovery in healthy adults.
  • It does not prove internet products match studied material.
  • It does not establish approval for recovery, anti-aging or performance uses.

What should you do with this information?

  • Use it to ask better questions, not to self-experiment.
  • Do not use this page for dosing, sourcing, stacking or self-administration decisions.
  • Speak with a qualified clinician before acting on high-risk claims.

What not to do

  • Do not self-administer based on this page.
  • Do not use this page for dosing, sourcing, stacking, cycle planning or injection instructions.
  • Do not start, stop or combine drugs, peptides, supplements or experimental interventions without a qualified clinician.

Questions to ask a qualified clinician

  1. What exact medical indication is being discussed, and is it approved for that use?
  2. What human evidence exists for my situation, not just animals, cells or biomarkers?
  3. What monitoring, contraindications and interaction questions matter before any decision?
  4. What outcome would show benefit, and what outcome would show harm or no effect?

Want the deeper version?

Open these sections if you want the source detail, regulatory context and expert notes.

Show the evidenceSources, study type and where the claim gets weaker.+
Fda

FDA explains that compounded drugs are not FDA-approved and that FDA does not verify their safety, effectiveness or quality before marketing.

Publisher
FDA
Accessed
Jun 27, 2026
Study type
Regulatory Document

Limitations: Regulatory language is product-, jurisdiction- and use-specific. Always verify the current official page before relying on it.

Fda

FDA safety-risk context for nominated bulk substances used in compounding, relevant when internet peptide claims imply compounding equals approval.

Publisher
FDA
Accessed
Jun 27, 2026
Study type
Regulatory Document

Limitations: Regulatory language is product-, jurisdiction- and use-specific. Always verify the current official page before relying on it.

Other

Official anti-doping source for prohibited classes, including unapproved substances and peptide-related categories.

Publisher
WADA
Accessed
Jun 27, 2026
Study type
Regulatory Document

Limitations: The prohibited list is an anti-doping document, not a consumer medical-safety guide.

Clinicaltrials

Shows whether human studies match the broad recovery claim.

Publisher
ClinicalTrials.gov
Accessed
Jun 27, 2026
Study type
Regulatory Document

Limitations: Trial registration does not prove benefit; it shows a study has been registered.

Weakest link in the claim

  • The weak link is translating mechanism into unsupervised injury-recovery claims.
Show regulatory detailApproval status is use-specific. Internet claims may not match reviewed uses.+
Status:Not approvedWho might profit:Clinic incentive
Show expert notesWhat would change our mind, money trail and related claims.+

What would change our mind

  • Controlled human trials in defined injury populations.
  • Transparent product identity and regulatory clarity.
  • Replication by independent groups.

Money trail

Who might profit:Clinic incentive

Commercial context does not automatically make a claim false, but it changes how carefully the claim should be read.

  • TB-500 is often sold through recovery-oriented offers, which raises commercial-context questions.

FAQs

Does this page give a protocol?

No. LHN claim checks explain evidence, risk, regulatory status and source context. They do not provide personal medical instructions.

Is TB-500 the same as thymosin beta-4?

Not exactly. Claims often blur related biology with product-specific evidence.

Related claims

LHN branded editorial cover for claim check: Does rapamycin slow aging in humans?.

Longevity drugs

Does rapamycin slow aging in humans?

Rapamycin has unusually strong aging-biology interest, but it is not proven to slow human aging or extend lifespan in healthy adults.

Evidence:Human trial evidenceRisk:High risk

Updated Jun 27, 2026 · Promising, not settled

Read the simple answer

Related guides

Get the weekly longevity evidence briefing.

One plain-English email on the claims, studies and regulatory updates worth knowing - without protocols, hype or miracle claims.

No protocols. No miracle claims. No spam.

Choose your interests